Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Fumihiko SakaiNorihiro SuzukiByung-Kun KimHisaka IgarashiKoichi HirataTakao TakeshimaXiaoping NingTomoko ShimaMiki IshidaKatsuhiro IbaHiroyuki KondoNobuyuki KogaPublished in: Headache (2021)
Fremanezumab effectively prevents CM in Japanese and Korean patients and was well tolerated. No safety signal was detected.
Keyphrases
- double blind
- placebo controlled
- end stage renal disease
- phase iii
- clinical trial
- ejection fraction
- newly diagnosed
- phase ii
- chronic kidney disease
- prognostic factors
- study protocol
- randomized controlled trial
- peritoneal dialysis
- open label
- squamous cell carcinoma
- patient reported outcomes
- mouse model
- cross sectional
- locally advanced